Business Details
Innovative Cancer Therapies Development
Leaf Pharmaceuticals is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and commercializing innovative therapies targeting high unmet medical needs in oncology. Founded on the principle of leveraging scientific advances to re-engineer promising molecules, the company focuses on creating safer, more effective treatments for cancer patients worldwide. Our multidisciplinary teams combine decades of expertise in molecular biology, biochemistry, and drug development to address challenges in solid tumor treatment. We prioritize accessibility, particularly in emerging economies, ensuring life-saving therapies reach underserved populations.Backed by a leadership team with extensive regulatory and clinical research experience, including approvals of groundbreaking drugs like ONIVYDE and ALIMTA, we maintain rigorous adherence to quality and innovation. Our collaborations with global institutions and recognition through awards like the 2016 Health Care Innovator Award underscore our commitment to advancing cancer care. By integrating cutting-edge research with ethical practices, we strive to empower families affected by cancer through transformative medical solutions.
Services
Oncology Drug Development
Molecular Re-engineering
Clinical Research
Regulatory Strategy
Global Health Initiatives
Highlights and features
- Global reach with focus on emerging economies
- Pioneering antifolate resistance research
- Leadership with FDA-approved drug experience
- Commitment to affordable cancer treatments
- Collaborations with top research institutions
Associations and certifications
- 2016 Health Care Innovator Award
Services
Oncology Drug Development
Developing innovative treatments for solid tumors through molecular re-engineering. Our pipeline targets antifolate resistance mechanisms to improve efficacy. Expertise spans preclinical research to FDA approval processes, ensuring safe, accessible therapies for global patients.
Molecular Re-engineering
Transforming failed drug candidates into effective therapies by modifying molecular structures. This approach bypasses resistance pathways like GGH overexpression, enhancing treatment potency while preserving healthy cells in preclinical models.
People
Dr. Clet Niyikiza
Founder & CEO
Former Merrimack Pharmaceuticals executive with 25+ years in oncology drug development. Led approval of ONIVYDE for pancreatic cancer. Recipient of 2016 Health Care Innovator Award. Holds doctorate in Mathematics from Indiana University.
Dr. Daniel Von Hoff
Clinical Advisor
Physician-in-Chief at TGen with 40+ years experience in phase I trials. Pioneered development of 10+ standard cancer drugs. Recipient of ASCO's Karnofsky Award and SU2C Pancreatic Dream Team leadership.
Michael Slater
Regulatory Advisor
35+ years regulatory affairs expertise, including 100+ IND filings. Directed Onivyde approval strategy in US and Europe. Former Head of Regulatory Affairs at Merrimack Pharmaceuticals with biotech industry leadership roles.
Questions
What therapeutic areas does L.E.A.F. focus on?
We specialize in oncology, particularly solid tumors like pancreatic, lung, and colorectal cancers, addressing unmet needs through molecular innovation.
What pipeline products are in development?
Lead candidates LEAF-1401 and LEAF-1701 target antifolate resistance mechanisms in solid tumors, currently in IND-enabling GLP toxicology studies.
How does L.E.A.F. address drug resistance?
Our platform bypasses GGH-mediated resistance by designing polyglutamated analogs that maintain potency without requiring intracellular activation.
Who leads L.E.A.F.'s scientific initiatives?
Founder Dr. Clet Niyikiza oversees R&D, supported by advisors including Dr. Daniel Von Hoff and regulatory expert Michael Slater with decades of industry experience.
Where is L.E.A.F. Pharmaceuticals based?
Our main office is located at 10 R Gill Street, Woburn, MA 01801, with global research collaborations across North America and Europe.
